The Latest Cardiac and Vascular News
VALHALLA, N.Y., March 2, 2022 /PRNewswire/ — Retia Medical today announced that it received a Declaration of Compatibility from Philips for its Argos Cardiac Output Monitor to interface with Philips IntelliBridge system on the IntelliVue patient monitoring systems. The Argos Monitor is now a compatible and “supported device” for Philips IntelliVue Patient […]
DENVER and WASHINGTON, March 2, 2022 /PRNewswire/ — DispatchHealth, the nation’s first comprehensive in-home high acuity medical provider, today announced its collaboration with The American College of Cardiology (ACC), a nonprofit professional medical society, to enhance the lives of cardiovascular disease patients. The first of its kind, the collaboration between DispatchHealth and ACC is designed to […]
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]
The TicWatch GTH Pro features Arty® Heart Health technology, powered by ATCOR, a subsidiary of CardieX, to monitor arterial and heart health IRVINE, Calif. and SYDNEY, March 1, 2022 /PRNewswire/ — Mobvoi Inc., a leading artificial intelligence-wearable company backed by Google™ and Volkswagen, in partnership with global health tech company CardieX, today announces the launch of […]
– Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance after stabilization and before discharge compared with placebo – The benefit was consistent in adults with new or existing heart failure and in those with either preserved […]
SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to […]
PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart […]
Final 5-Year Data from BIOFLOW-V Trial Confirms Better Safety for Orsiro DES, Confirming Orsiro’s Position as the Clinical Benchmark for DES BÜLACH, Switzerland, Feb. 28, 2022 /PRNewswire/ — BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking clinical trial session by Dr. David […]
Data Presented at Cardiovascular Research Technologies (CRT) Annual Conference SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio this past weekend at the Cardiovascular Research Technologies (CRT) annual conference. The transcatheter TRIA […]
– Alignment signals recognition of Terumo Health Outcomes’ proprietary ePRISM® technology using precision medicine to improve outcomes for cardiac patients and Corazon accreditation as a means to monitor and recognize such improvements – SOMERSET, N.J., Feb. 25, 2022 /PRNewswire/ — Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global […]
